Want to see HK:6628 full AI Analyst Report?
Transcenta Holding Limited (6628) AI Stock Analysis
Transcenta Holding Limited
(HKEX:6628)
The score is primarily held down by weak financial performance (shrinking revenue, persistent losses, negative gross profit in 2025, and ongoing cash burn). Technicals add further pressure with a clear downtrend versus key moving averages and negative MACD. Valuation is only slightly supportive because a negative P/E indicates losses and there is no dividend yield provided.
Transcenta Holding Limited (6628) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 313.81M
- Dividend Yield
- ―
- Average Volume (3M)
- 758.06K
- Price to Earnings (P/E)
- -1.6
- Beta (1Y)
- 1.70
- Revenue Growth
- 215.14%
- EPS Growth
- 40.49%
- Country
- Hong Kong
- Employees
- 150
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Transcenta Holding Limited Business Overview & Revenue Model
Company Description
Transcenta Holding Limited is a clinical-stage biopharmaceutical company focused on the discovery, research, development, manufacturing, and commercialization of therapeutic agents within the People's Republic of China and the United States. The comp...
Transcenta Holding Limited Financial Statement Overview
Summary
Overall fundamentals are weak: revenue has contracted materially, profitability remains deeply negative, and 2025 shifted to negative gross profit. While leverage is manageable and improving, equity has been shrinking and both operating cash flow and free cash flow remain consistently negative despite some improvement in 2025 cash burn.
Income Statement
18Very NegativeBalance Sheet
58NeutralCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.32M | 7.24M | 11.26M | 53.85M | 101.89M | 50.24M |
| Gross Profit | 18.34M | -40.75M | 4.00M | 14.40M | 19.89M | 9.37M |
| EBITDA | -100.16M | -146.86M | -228.09M | -393.01M | -334.09M | -1.65B |
| Net Income | -161.29M | -198.45M | -290.29M | -462.57M | -406.75M | -1.72B |
Balance Sheet | ||||||
| Total Assets | 891.60M | 925.23M | 1.20B | 1.69B | 2.13B | 2.54B |
| Cash, Cash Equivalents and Short-Term Investments | 3.50M | 14.15M | 169.42M | 546.03M | 895.45M | 1.22B |
| Total Debt | 137.79M | 126.26M | 250.61M | 409.63M | 411.46M | 364.71M |
| Total Liabilities | 338.51M | 306.87M | 448.64M | 665.67M | 660.64M | 579.39M |
| Stockholders Equity | 553.09M | 618.36M | 751.64M | 1.03B | 1.47B | 1.97B |
Cash Flow | ||||||
| Free Cash Flow | -72.63M | -142.97M | -216.15M | -373.80M | -318.03M | -457.84M |
| Operating Cash Flow | -69.42M | -135.67M | -213.83M | -358.04M | -295.81M | -384.50M |
| Investing Cash Flow | 58.34M | 55.48M | 14.28M | 57.47M | -102.61M | -69.77M |
| Financing Cash Flow | -30.36M | -74.93M | -178.06M | -47.20M | 26.72M | 879.71M |
Transcenta Holding Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6628, the sentiment is Neutral. The current price of 0.73 is below the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.90, and below the 200-day MA of 1.65, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 46.62 is Neutral, neither overbought nor oversold. The STOCH value of 82.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6628.
Transcenta Holding Limited Peers Comparison
Overall Rating
HK:699870Outperform
HK:215753Neutral
HK:996652Neutral
HK:261646.6Neutral- HK:662843Neutral
HK:217139Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6998 | 70Outperform | HKD 3.26B | 4.48 | 10.99% | ― | 1417.68% | 660.14% |
| HK:2157 | 53Neutral | HKD 5.69B | 19.79 | 17.36% | ― | 46.90% | ― |
| HK:9966 | 52Neutral | HKD 6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2616 | 47Neutral | HKD 7.77B | -15.53 | -43.54% | ― | 116.67% | -0.42% |
| HK:6628 | 43Neutral | HKD 327.59M | -1.65 | -27.54% | ― | 215.14% | 40.49% |
| HK:2171 | 39Underperform | HKD 6.32B | -56.08 | -9.45% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6628 | Transcenta Holding Limited | 0.73 | -2.31 | -75.90% | |
| HK:6998 | Genor Biopharma Holdings Limited | 1.62 | -1.51 | -48.24% | |
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:2157 | Lepu Biopharma Co. Ltd. Class H | 3.15 | -3.23 | -50.55% | |
| HK:2171 | CARsgen Therapeutics Holdings Ltd. | 10.63 | -6.92 | -39.43% | |
| HK:2616 | CStone Pharmaceuticals | 4.94 | -1.28 | -20.58% |
Transcenta Holding Limited Corporate Events
Transcenta Seeks Shareholder Approval to Expand Equity Incentive Scheme
Transcenta Holding Limited has called an extraordinary general meeting for November 19, 2026, in Suzhou, China, to seek shareholder approval to refresh the mandate limit of its Share Incentive Scheme. The proposal would allow the company to issue new...
Transcenta Advances Licensing and Funding Drive to Ease Liquidity and Address Audit Disclaimer
Transcenta Holding Limited said it is pressing ahead with nine measures to ease liquidity pressures and strengthen its balance sheet, as it works to resolve a disclaimer of opinion raised in its 2025 annual report. The group is actively pursuing part...
Transcenta Receives First RMB95 Million Payment from Sale of CDMO Assets
Transcenta Holding Limited has received the first after-tax payment of RMB95 million from the sale of its CDMO assets to a wholly owned subsidiary of WuXi Biologics, under a total consideration of RMB190 million. The proceeds will be directed to gene...
Transcenta Bolsters Claudin18.2 IP With New China Patent Backing Global Osemitamab Push
Transcenta Holding Limited has strengthened its intellectual property portfolio around its flagship Claudin18.2-targeting program, osemitamab (TST001), with a new China invention patent granted for anti-CLDN18.2 antibodies and their diagnostic uses....
Transcenta Revises Share Incentive Grant for Director Prof. Genhong Cheng
Transcenta Holding Limited has revised the share-based remuneration for Director Prof. Genhong Cheng by cancelling a previous grant of 30,000 award shares that had not yet been transferred and replacing it with a new grant of the same number of share...
Transcenta Shareholders Unanimously Approve Asset Purchase Deal
Transcenta Holding Limited, a Cayman Islands–registered biopharmaceutical company listed on the Hong Kong Stock Exchange, operates from Suzhou’s Biobay in China, where it develops and commercializes biologic therapies for healthcare marke...
Transcenta Adds Independent Director, Restores Compliance and Grants Share Award
Transcenta Holding Limited has appointed renowned microbiology and immunology expert Prof. Genhong Cheng as an independent non-executive director, effective August 28, 2026, bolstering the scientific depth and governance expertise of its board. His a...
Transcenta Sets Out Board Composition and Committee Roles
Transcenta Holding Limited has disclosed the current composition of its board, led by Chief Executive Officer and Chairman Dr. Xueming Qian as the sole executive director, alongside two non-executive directors and three independent non-executive dire...
Transcenta Narrows Loss as Revenue Surges on Out-Licensing and CDMO Growth
Transcenta reported a sharp rise in interim revenue to RMB23.6 million for the six months ended June 30, 2026, up from RMB2.7 million a year earlier, mainly driven by higher out-licensing income and expanded CDMO services. The shift indicates growing...
Transcenta Calls Extraordinary Meeting to Approve Asset Purchase Deal
Transcenta Holding Limited, registered by way of continuation in the Cayman Islands and listed on the Hong Kong Stock Exchange, maintains its principal operations hub in Hong Kong while convening key corporate meetings in Suzhou, China. The company&#...
Transcenta Sets September EGM and Record Date for Asset Purchase Vote
Transcenta Holding Limited has scheduled an extraordinary general meeting for September 9, 2026, in Suzhou, China, where shareholders will be asked to consider and, if appropriate, approve an Asset Purchase Agreement and the related transaction. The...
Transcenta Sets August Board Meeting to Review Interim Results and Dividend
Transcenta Holding Limited has scheduled a board meeting for August 28, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026, and to consider the recommendation of an interim dividend. The meeting signal...
Transcenta to Sell Hangzhou CDMO Assets to WuXi Biologics for RMB190 Million
Transcenta Holding Limited has agreed to dispose of its CDMO assets in Hangzhou for a total consideration of RMB190 million, exiting ownership of a CDMO plant, related land use rights, buildings, equipment and associated operational assets. The buyer...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026